Monday, September 20, 2021
HomeBusinessWSJ News Exclusive | J&J Contractor Plans to Resume Covid-19 Vaccine Production...

WSJ News Exclusive | J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant

WASHINGTON—Emergent BioSolutions Inc. plans to resume Covid-19 vaccine production at its Baltimore plant after getting the green light from the Food and Drug Administration, according to a statement from the company and an FDA letter reviewed by the Journal.

“We are proud to be resuming production of bulk Covid-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners,” Emergent CEO Robert Kramer said in a statement late Wednesday. “We are grateful for the opportunity to help bring this global pandemic to an end.”

The plant makes vaccines for Johnson & Johnson.

While domestic demand for the Johnson & Johnson shot has dwindled in recent months, the Biden administration is seeking the shots to be exported to countries needing protection against Covid-19.

The Baltimore plant had been shut down after FDA inspectors determined there was severe contamination at the plant.



Please enter your comment!
Please enter your name here


Most Popular